Showing results (281-290 of 494) with videos related to
Sort By:
Pageof 50
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 19, 2024
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr Błoński, et al.Melanoma Research|November 9, 2020
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patientsBożena Cybulska-Stopa, Marcin Ziętek, Grażyna Kamińska-Winciorek, et al.Targeted Oncology|June 24, 2025
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SDAnna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, et al.International Journal of Cancer|June 9, 2004
Increased cancer risk of heterozygotes with NBS1 germline mutations in PolandJan Steffen, Raymonda Varon, Maria Mosor, et al.European Journal of Cancer (Oxford, England : 1990)|November 10, 2019
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenibDirk Schadendorf, Anna Maria Di Giacomo, Lev Demidov, et al.Tumori|February 7, 2020
Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysisKatarzyna Kozak, Artur Kowalik, Aleksandra Gos, et al.European Journal of Cancer (Oxford, England : 1990)|August 12, 2020
SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessmentAnna Szumera-Ciećkiewicz, Francesca Bosisio, Paweł Teterycz, et al.European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.European Journal of Cancer (Oxford, England : 1990)|September 27, 2016
Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survivalCharlotte M C Oude Ophuis, Alexander C J van Akkooi, Piotr Rutkowski, et al.Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.Pageof 50